HONG KONG, May 21, 2025 – We are thrilled to announce that today, May 21, 2025, Eagle IP celebrates its 20th anniversary, marking two decades of dedication to client success and innovation in patent law. Founded on May 21, 2005 by Dr. Jacqueline Lui (Jackie), the firm has grown from its humble beginnings into a respected name in the industry.

In a recent team celebration, Jackie, the firm’s founder, shared her reflections on Eagle IP’s journey. “Starting Eagle IP was a leap of faith driven by my commitment to my clients and their patent portfolios,” she said. “Transferring two significant portfolios laid the foundation for the beginnings of the firm and paved the way towards our success. I’m grateful for the perseverance that carried us through tough times. Our CPR culture—caring, professional, and responsive—has defined who we are and will guide us forward.”

The anniversary event highlighted the firm’s strong culture, with team members who have been with the firm for over a decade sharing memories of growth under Jackie’s leadership.

Jennifer Che, current President and Managing Director who “took the baton” of Eagle IP leadership last year from Jackie, expressed her commitment to upholding these values while driving expansion, noting the firm’s increasing client base and active participation in global conferences.

Eagle IP looks to the future with optimism, dedicated to maintaining its high standards, fostering continuous learning, and building stronger team relationships. Jackie and her husband HC Lui emphasized the power of teamwork, assuring continued support as the firm embarks on its next chapter.

A huge THANK YOU to all our clients, mentors, and colleagues who have supported us through the years.

我们的过去活动

Recommended Insights

NMPA's Releases Draft Measures for Data Protection (Data Exclusivity)

2025年9月4日
In March 2025, China's National Medical Products Administration (NMPA) released yet another set of draft implementation measures on data protection.1 Key highlights of these new measures include the following: A Bit of History China's journey toward a comprehensive pharmaceutical data protection framework has been ongoing for over two decades, a roller coaster ride from its […]

Compositions Limited by Use: A Cautionary Tale

2022年10月26日
Section 4.2.3, Part II Chapter 10 of the CNIPA’s Examination Guidelines (“Guidelines”) stipulates that if the specification only discloses one property or use of a composition, the composition claim shall be drafted as a “composition limited by the function or the use”. Furthermore, it specifically states that “most pharmaceutical claims shall be drafted as claims […]

New Policies to Promote Importation of Innovative Drugs

2018年11月8日
At the April 12, 2018 executive meeting of the State Council in China, Premier Mr. Li Keqiang indicated the government’s desire to increase China’s access to innovative drugs. To achieve this, the government would encourage importation of innovative drugs into China by streamlining the regulatory pathway, enhancing IP protection, and lowering the cost of medicine. […]

How a Secondhand Ground Brush Wiped Away a Chinese Patent

2024年12月4日
A Chinese robot vacuum company digs up “hidden evidence” to successfully invalidate a patent owned by its biggest competitor.  Highlights Background  With the growth of online shopping, it is easier than ever to provide evidence of a sale when the product is still being sold on the market. But what if the product is no […]
Top crossarrow-right